查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654329

全球止血诊断市场：市场规模、份额、趋势分析（按产品、测试、最终用途和地区）、细分市场预测（2025-2030 年）

Hemostasis Diagnostics Market Size, Share & Trends Analysis Report By Product (POC Testing Systems, Consumables), By Test (Prothrombin Time Test, D Dimer Test), By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

止血诊断市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球止血诊断市场规模预计到2030年将达到14.9亿美元，2025年至2030年复合年增长率为4.5%。

由于全球老年人口增加、诊断技术的进步、对出血和凝血障碍的认识不断提高以及慢性病患病率上升等各种因素，市场可能会呈现显着增长。

推动市场发展的因素之一是老年人口的不断增长。随着人口老化，患有影响止血的疾病的可能性增加，例如静脉血栓栓塞症、心房颤动和其他心血管疾病。老年人也更有可能接受需要精确监测凝血程度的手术，以避免过度出血和血栓形成等併发症。这些人口趋势正在推动对能够评估血液凝固和出血风险的诊断工具的需求。

产品开发技术的进步也促进了市场的发展。先进、准确的诊断分析仪（如照护现场设备）的开发使得医疗保健提供者能够更容易地在各种医疗环境中快速监测凝血参数。这些进步提高了诊断止血疾病的速度和效率，这在紧急和紧急医疗环境中尤其重要。

此外，自动分析仪和分子诊断测试等测试平台的创新扩大了可用的测试范围，并且可以更准确地检测出血和凝血障碍的根本原因。

由于新兴国家正在进行的研究，人们对出血性疾病的认识和理解不断提高，从而推动了治疗药物市场的成长。公共卫生宣传活动和医学研究强调了早期诊断和介入对于血友病、深层静脉栓塞症（DVT）和肺动脉栓塞等疾病管理的重要性。因此，人们越来越重视对有这些疾病风险的患者进行定期筛检和监测，从而增加了对止血诊断测试的需求。

慢性病，特别是心血管系统相关疾病的发生率不断上升，也促进了市场的成长。心血管疾病常常导致凝血障碍，这是由于动脉中血栓形成以及使用抗凝血疗法来预防中风和心臟病发作造成的。随着越来越多的人被诊断出患有慢性心血管疾病，对能够监测血液凝固和出血风险的诊断测试的需求也日益增加，从而进一步推动市场的发展。

此外，个人化医疗的兴起正在对止血诊断市场产生影响。在止血方面，个人化医疗可以帮助识别出血和血液凝固障碍高风险的患者，从而使医疗保健提供者能够选择最合适的诊断测试和治疗方法。这一趋势正在推动更具针对性的诊断工具的开发，以满足个别患者的特定需求。

市场的主要企业包括 F. Hoffmann-La Roche AG、丹纳赫集团、Sysmex 公司、西门子医疗、Horiba Medical、Haemonetics 公司、HemoSonics, LLC、Sterile Safequip and Chemicals LLP、TECO Medical Instruments 和 Stago。这些公司选择的主要策略包括产品开发创新，例如推出更先进的自动化照护现场诊断设备，以提供更快、更准确的结果。与医院、研究机构和其他医疗保健提供者建立策略联盟和合作对于扩大我们的市场范围和增强我们的产品供应也至关重要。此外，每家公司都致力于扩大产品系列，以涵盖更广泛的诊断测试，以满足常规和特殊测试需求。

止血诊断市场：分析概述

  • 按产品类型划分，消耗品将占据最大的销售份额，到 2024 年将达到 61.1%。随着测试数量的增加，预测期内对消耗品的需求可能会呈现良好的成长。
  • 根据测试，凝血酶原时间测试将占据市场主导地位，到 2024 年将占据 31.5% 的最大份额。 PT 测试可以在各种医疗保健环境中进行，包括医院、诊所甚至照护现场，更容易及时诊断和治疗。此外，此测试的周转时间相对较短，可让临床医生快速做出有关患者护理的决策。
  • 根据最终用途，医院部门占据市场主导地位，2024 年的收入份额最大，为 57.7%。这一领域占据主导地位，是因为医院中接受检测的患者数量庞大。
  • 北美凭藉完善的医疗保健基础设施占据了全球市场的主导地位，能够及时诊断和管理患有出血和凝血障碍的患者。
  • 预计亚太地区将以最快的速度成长，2025 年至 2030 年的预测期内复合年增长率为 5.1%。这是由于新兴市场医疗设施的增加。此外，对预防性常规检测的日益关注也支持了市场的成长。

目录

第一章 分析方法及范围

第 2 章执行摘要

第 3 章 止血诊断市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 止血诊断市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL 分析

第 4 章 止血诊断市场：按产品分類的估计与趋势分析

  • 按产品市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球止血诊断市场（按产品）展望
  • 市场规模预测及趋势分析（2018-2030年）
    • 实验室分析设备
    • 就地检验系统
    • 耗材

第 5 章 止血诊断市场：测试估计与趋势分析

  • 测试市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球止血诊断市场前景（按测试）
  • 市场规模预测及趋势分析（2018-2030年）
    • 活化部份凝血活酵素时间
    • D-二聚体检测
    • 纤维蛋白原检测
    • 凝血酶原时间 (PT) 测试
    • 其他测试

第 6 章止血诊断市场：按最终用途的估计和趋势分析

  • 按最终用途分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球止血诊断市场前景（依最终用途划分）
  • 市场规模预测及趋势分析（2018-2030年）
    • 医院
    • 诊断实验室
    • 其他的

第 7 章 止血诊断市场：按地区分類的估计和趋势分析

  • 各地区市场占有率（2024 年及 2030 年）
  • 区域控制面板
  • 全球止血诊断市场区域展望
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • Key company market share analysis, 2024
    • F. Hoffmann-La Roche AG
    • Danaher Corporation
    • Sysmex Corporation
    • Siemens Healthineers
    • Horiba Medical
    • Haemonetics Corporation
    • HemoSonics, LLC
    • Sterile Safequip and Chemicals LLP
    • TECO Medical Instruments
    • Stago
Product Code: GVR-4-68040-502-3

Hemostasis Diagnostics Market Growth & Trends:

The global hemostasis diagnostics market size is expected to reach USD 1.49 billion by 2030, registering a CAGR of 4.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is likely to show significant growth due to various factors, such as the growing geriatric population across the globe, advancements in diagnostic technologies, increasing awareness of bleeding and clotting disorders, and the rising prevalence of chronic diseases.

One of the primary drivers of the market is the growing geriatric population. As people age, the likelihood of developing conditions that affect hemostasis, such as venous thromboembolism, atrial fibrillation, and other cardiovascular diseases, increases. Older individuals are also more likely to undergo surgeries that require accurate monitoring of coagulation levels to avoid complications like excessive bleeding or clot formation. This demographic trend is boosting the demand for diagnostic tools that can assess blood clotting and bleeding risks.

Technological advancements in terms of product development are also contributing to market growth. The development of sophisticated and accurate diagnostic analyzers, such as point-of-care devices, has made it easier for healthcare providers to quickly monitor coagulation parameters across various healthcare settings. These advancements have improved the speed and efficiency of diagnosing hemostasis disorders, which is particularly important in emergency and critical care settings.

In addition, innovations in testing platforms, such as automated analyzers and molecular diagnostic tests, have expanded the range of tests available, allowing for more precise detection of underlying causes of bleeding and clotting disorders.

Increased awareness and better understanding of bleeding disorders owing to continuous research in emerging economies are driving the growth of the hemostasis diagnostics market. Public health campaigns and medical research have highlighted the importance of early diagnosis and intervention in managing conditions such as hemophilia, deep vein thrombosis (DVT), and pulmonary embolism. As a result, there is a greater emphasis on regular screening and monitoring of patients at risk of these conditions, which increases the demand for hemostasis diagnostic tests.

The rising prevalence of chronic diseases, particularly those related to the cardiovascular system, is also contributing to the growth of the market. Cardiovascular diseases often lead to clotting disorders, either due to the formation of blood clots in the arteries or the use of anticoagulant therapies to prevent strokes and heart attacks. As more individuals are diagnosed with chronic cardiovascular conditions, there is an increased need for diagnostic tests that can monitor blood clotting and bleeding risks, further driving the market.

Furthermore, the growing adoption of personalized medicine is playing a role in the hemostasis diagnostics market. In the context of hemostasis, personalized medicine can help identify patients who are at higher risk of bleeding or clotting disorders, enabling healthcare providers to choose the most appropriate diagnostic tests and treatments. This trend is encouraging the development of more targeted diagnostic tools that can cater to the specific needs of individual patients.

Some key players in the market are F. Hoffmann-La Roche AG; Danaher Corporation; Sysmex Corporation; Siemens Healthineers; Horiba Medical; Haemonetics Corporation; HemoSonics, LLC; Sterile Safequip and Chemicals LLP; TECO Medical Instruments; Stago and more. Key strategies opted by the companies include innovation in product development, such as introducing more advanced, automated, and point-of-care diagnostic devices that offer faster, more accurate results. Strategic partnerships and collaborations with hospitals, research institutions, and other healthcare providers are also crucial for expanding market reach and enhancing product offerings. Additionally, companies are focusing on expanding their product portfolios to include a broader range of diagnostic tests, catering to both routine and specialized testing needs.

Hemostasis Diagnostics Market Report Highlights:

  • Based on product, consumables accounted for the largest revenue share of 61.1% in 2024. With the increasing number of tests being performed, the demand for consumables is likely to show lucrative growth over the forecast period.
  • Based on test, the prothrombin time test dominated the market and accounted for the largest share of 31.5% in 2024.The PT test can be performed in various healthcare settings, including hospitals, clinics, and even point-of-care locations, making it accessible for timely diagnosis and treatment. Additionally, the test has a relatively short turnaround time, allowing clinicians to make rapid decisions regarding patient care.
  • Based on end use, the hospitals segment dominated the market with the largest revenue share of 57.7% in 2024. The segment dominance is attributed to large patient volumes being tested in hospitals.
  • North America dominated the global market owing to well-established healthcare infrastructure allowing timely diagnosis and management of patients with bleeding and clotting disorders.
  • The Asia Pacific region is expected to witness the fastest growth with a CAGR of 5.1% over the forecast period from 2025 to 2030, due to the development of healthcare facilities across emerging markets. Furthermore, increasing focus on preventive routine testing is also supporting the market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Test
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test outlook
    • 2.2.2. Product outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hemostasis Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Bleeding Disorders
      • 3.2.1.2. Technological Advancements
      • 3.2.1.3. Awareness of Preventive Healthcare
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Advanced Devices
      • 3.2.2.2. Lack of Skilled Personnel
  • 3.3. Hemostasis Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Hemostasis Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Hemostasis Diagnostics Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Laboratory Analyzers
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Automated Systems
        • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Semi-automated Systems
        • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Manual Systems
        • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Point-of-Care Testing Systems
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Consumables
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Hemostasis Diagnostics Market: Test Estimates & Trend Analysis

  • 5.1. Test Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Hemostasis Diagnostics Market by Test Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Activated Partial Thromboplastin Time
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. D-Dimer Test
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Fibrinogen Test
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Prothrombin Time (PT) Test
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Other Tests
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Hemostasis Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Hemostasis Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Diagnostic Laboratories
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Hemostasis Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Target disease prevalence
      • 7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Target disease prevalence
      • 7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Target disease prevalence
      • 7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Target disease prevalence
      • 7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Target disease prevalence
      • 7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Target disease prevalence
      • 7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. Target disease prevalence
      • 7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Target disease prevalence
      • 7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Target disease prevalence
      • 7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Target disease prevalence
      • 7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Target disease prevalence
      • 7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. Target disease prevalence
      • 7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Target disease prevalence
      • 7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Target disease prevalence
      • 7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Target disease prevalence
      • 7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company market share analysis, 2024
    • 8.3.2. F. Hoffmann-La Roche AG
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Danaher Corporation
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Sysmex Corporation
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Siemens Healthineers
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Horiba Medical
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Haemonetics Corporation
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. HemoSonics, LLC
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Sterile Safequip and Chemicals LLP
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. TECO Medical Instruments
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Stago
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives

List of Tables

  • Table. 1 List of Abbreviation
  • Table. 2 North America hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 3 North America hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 4 North America hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 5 U.S. hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 6 U.S. hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 7 U.S. hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 8 Canada hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 9 Canada hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 10 Canada hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 11 Mexico hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 12 Mexico hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 13 Mexico hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 14 Europe hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 15 Europe hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 16 Europe hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 17 UK hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 18 UK hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 19 UK hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 20 Germany hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 21 Germany hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 22 Germany hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 23 France hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 24 France hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 25 France hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 26 Italy hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 27 Italy hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 28 Italy hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 29 Spain hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 30 Spain hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 31 Spain hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 32 Denmark hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 33 Denmark hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 34 Denmark hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 35 Sweden hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 36 Sweden hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 37 Sweden hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 38 Norway hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 39 Norway hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 40 Norway hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 41 Asia Pacific hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 42 Asia Pacific hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 43 Asia Pacific hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 44 Japan hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 45 Japan hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 46 Japan hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 47 China hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 48 China hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 49 China hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 50 India hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 51 India hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 52 India hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 53 Australia hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 54 Australia hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 55 Australia hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 56 Thailand hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 57 Thailand hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 58 Thailand hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 59 South Korea hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 60 South Korea hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 61 South Korea hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 62 Latin America hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 63 Latin America hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 64 Latin America hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 65 Brazil hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 66 Brazil hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 67 Brazil hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 68 Argentina hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 69 Argentina hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 70 Argentina hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 71 Middle East & Africa hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 72 Middle East & Africa hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 73 Middle East & Africa hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 74 South Africa hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 75 South Africa hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 76 South Africa hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 77 Saudi Arabia hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 78 Saudi Arabia hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 79 Saudi Arabia hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 80 UAE hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 81 UAE hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 82 UAE hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 83 Kuwait hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 84 Kuwait hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 85 Kuwait hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Hemostasis Diagnostics: Market outlook
  • Fig. 9 Hemostasis Diagnostics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Hemostasis Diagnostics Market driver impact
  • Fig. 15 Hemostasis Diagnostics Market restraint impact
  • Fig. 16 Hemostasis Diagnostics Market strategic initiatives analysis
  • Fig. 17 Hemostasis Diagnostics market: Product movement analysis
  • Fig. 18 Hemostasis Diagnostics market: Product outlook and key takeaways
  • Fig. 19 Laboratory Analyzers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Point-of-Care Testing Systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Automated Systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Semi-automated Systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Manual Systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Hemostasis Diagnostics market: Test movement analysis
  • Fig. 26 Hemostasis Diagnostics market: Test outlook and key takeaways
  • Fig. 27 Activated Partial Thromboplastin Time market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 D-Dimer Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Fibrinogen Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Prothrombin Time (PT) Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Other Tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Hemostasis Diagnostics market: End Use movement analysis
  • Fig. 33 Hemostasis Diagnostics market: End Use outlook and key takeaways
  • Fig. 34 Hospitals hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Diagnostic Laboratories hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Others hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 North America hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Canada hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 UK hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Germany hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 France hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Italy hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Spain hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Norway hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Denmark hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Japan hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 China hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 India hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Australia hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Thailand hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Latin America hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Brazil hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Argentina hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Middle East and Africa. hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Saudi Arabia hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 South Africa hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 UAE hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Kuwait hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)